Tetraphase Pharmaceuticals Inc. is closer to filing for FDA and EMA approval of eravacycline – the drug could become only the second tetracycline antibiotic cleared in more than 30 years – after reporting positive top-line data from the phase III IGNITE 1 study in complicated intra-abdominal infections (cIAIs) testing eravacycline against ertapenem.